Cybin (HELP) Income from Continuing Operations (2020 - 2022)
Cybin (HELP) reported Income from Continuing Operations of 4552410.37 for Q2 2022, up 146.6% quarter-over-quarter from 9768785.54 in Q1 2021.
Cybin (HELP) Income from Continuing Operations (2020 - 2022) Analysis & Trends
Cybin has reported Income from Continuing Operations for 3 years, with the latest figure at 4552410.37 in Q2 2022.
- For the quarter ending Q2 2022, Income from Continuing Operations changed N/A year-over-year to 4552410.37; the trailing twelve-month figure through May 2022 stood at 15855786.46 (changed N/A YoY), and the FY2023 full-year result was 20291911.64, changed N/A from the prior year.
- Income from Continuing Operations for Q2 2022 stood at 4552410.37, up from 9768785.54 in the prior quarter.
- The five-year high for Income from Continuing Operations was 4552410.37 in Q2 2022, with the low at 9768785.54 in Q1 2021.
- Historically, Income from Continuing Operations has averaged 3779853.42 across 3 years, with a median of 3043480.66 in 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Cybin | 75.42 Mn | 75.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2022 | 4.55 Mn |
| Mar 31, 2021 | -9.77 Mn |
| Dec 31, 2020 | -8.72 Mn |
| Sep 30, 2020 | -1.92 Mn |
| Jun 30, 2020 | -3.04 Mn |